Advanced Glycation End Products Market, By Type (Non-fluorescent AGEs and Fluorescent AGEs), By Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024

Code : CMI4350

Pages :105

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Advanced Glycation End Products Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing lifespan and aging population

With significant improvements in public health and modern medicine there has been increase in life expectancy. People are now living longer than before. However, aging is an important risk factor for several chronic and degenerative diseases. As human body grows older, the natural process of AGE accumulation also accelerates due to slower tissue turnover and repair mechanisms. Aged tissues and organs exhibit markedly elevated AGE levels as compared to the young people. Aging is often accompanied by gradual decline in kidney function, which impairs the elimination of AGEs from the circulation. All these age-related changes increase burden of AGE. With growing geriatric population, age-related conditions requiring long-term management also increases. Thus, rising population of elderly individuals can boost use of anti-AGE therapies for the prevention and treatment of accelerated aging and age-related pathologies. New research exploring the pathological effects of AGEs have also drawn scientific and clinical interest in AGE-targeted drug development for different aging populations.

Key Players Insights